The adenosine receptor; a new pharmacological tool in the treatment of sepsis.

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-002860-86-NL

Enrollment

Registered

2007-06-13

Start date

2007-06-26

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic inflammatory response

Interventions

Product Name: LPS Pharmaceutical Form: Powder for solution for injection Product Name: Caffeine Pharmaceutical Form: Powder for solution for infusion Pharmaceutical form of the placebo: Solution for

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: healthy male volunteers age 18-35 years non-smokers no relevant medical history no history of syncope Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: smokers relevant medical history history of syncope use of medication

Design outcomes

Primary

Measure	Time frame
Main Objective: Finding a new tool in the treatment of sepsis, by pharmalogical intervention in a controlled model of systemic inflammation.;Secondary Objective: ;Primary end point(s): Markers of inflammation / Cytokine release Hemodynamic characteristics Symptom score Temperature Vascular dysfunction Markers of organ/tissue injury	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026